anselamimab

Drug Overview

The medication known as anselamimab (formerly referred to by the laboratory code CAEL-101 or 11-1F4) is an investigational “first-in-class” monoclonal antibody designed to treat Systemic Light Chain (AL) Amyloidosis. Unlike traditional therapies that target the source of the disease (the plasma cells), anselamimab is a “fibril depleter” that targets the toxic deposits already lodged in vital organs.

Developed by Alexion (AstraZeneca Rare Disease), anselamimab represents a shift from “prevention” to “removal” in the treatment of amyloidosis. It is specifically engineered to clear misfolded protein fibrils that interfere with heart and kidney function, potentially reversing organ damage in patients with advanced disease.

• Generic Name: Anselamimab.
• Other Names: CAEL-101, mAb 11-1F4.
• Drug Class: Amyloid Fibril-Reactive Monoclonal Antibody.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. As of early 2026, it is not yet FDA-approved. It holds Orphan Drug Designation in the US and EU. Following a mixed readout from the Phase 3 CARES program in late 2025, AstraZeneca has reportedly filed for marketing authorization in the EU based on promising results in specific patient subgroups.

What Is It and How Does It Work? (Mechanism of Action)

The Targeted Neoepitope

Anselamimab is a chimeric antibody that recognizes a specific, hidden “neoepitope”—a structural feature that only appears when immunoglobulin light chains misfold into toxic fibrils. Because it only binds to these misfolded proteins, it spares the healthy, circulating light chains the body needs for immune defense.

Molecular Level Mechanisms

1. Direct Fibril Binding: Once infused, anselamimab travels to organs (heart, kidneys, liver) and locks onto the amyloid fibrils.
2. Phagocytic Recruitment: The antibody “flags” the amyloid deposits for the immune system. It recruits macrophages (specialized scavenger cells) to the site.
3. Active Clearance: Through a process called Antibody-Dependent Cellular Phagocytosis (ADCP), the macrophages engulf and digest the amyloid fibrils, physically removing the deposits from the organ tissue.
4. Organ Recovery: By reducing the “amyloid burden” in the heart and kidneys, the drug aims to restore structural integrity and functional capacity, potentially extending survival in patients with severe cardiac involvement (Mayo Stages IIIa and IIIb).

FDA Approved Clinical Indications

Anselamimab is currently available only through participation in clinical trials or expanded access programs. It is being studied for:

Oncological/Hematological Uses (In Clinical Trials):

• Newly Diagnosed AL Amyloidosis: Evaluated in combination with the current standard of care (CyBorD + Daratumumab).
• Cardiac AL Amyloidosis (Advanced): Specifically targeting patients with Mayo Stage IIIa and IIIb disease, where the risk of mortality is highest.

Non-oncological Uses:

• There are currently no non-oncological uses for anselamimab.

Dosage and Administration Protocols

In the Phase 3 CARES clinical program, anselamimab was administered as an adjunct to standard therapy.

Clinical Efficacy and Research Results

The clinical journey of anselamimab has reached a pivotal and complex stage as of 2026.

• Phase 3 CARES Results (2025): The high-level results from the Phase 3 trials (NCT04512235 and NCT04504825) showed that the drug did not meet its primary endpoint of improving all-cause mortality and frequency of cardiovascular hospitalizations across the entire study population.
• Subgroup Promise: Despite the overall failure, AstraZeneca reported a clinically meaningful improvement in survival and heart function within a pre-specified subgroup of patients. This data forms the basis of recent regulatory filings in the EU (February 2026).
• Organ Response: Earlier Phase 1a/b data demonstrated that anselamimab could induce rapid organ responses (improvement in NT-proBNP and proteinuria) in up to 60% to 70% of evaluable patients.

Safety Profile and Side Effects

Anselamimab is generally considered safe and well-tolerated, with a side-effect profile that differs from traditional chemotherapy.

Common Side Effects (>10%):

• Infusion-Related Reactions: Chills, fever, or mild rash during the IV process.
• Fatigue: General tiredness.
• Nausea: Usually mild.
• Anemia: Though often related to the underlying amyloidosis or standard treatment.

Serious Adverse Events:

• Cardiac Events: While rare, some patients with severe heart involvement may experience worsening symptoms during the initial phase of amyloid clearance.
• Hypersensitivity: Rare cases of severe allergic reactions to the chimeric antibody.
• Management Strategies: Patients are typically pre-medicated with antihistamines and steroids to prevent infusion reactions. Cardiac monitoring is strictly performed in the early cycles.

Research Areas

In the field of Regenerative Medicine, anselamimab is a landmark therapy for studying “In Situ Tissue De-clogging.” Researchers are using anselamimab to understand how the heart and kidneys can regenerate once the physical “scaffolding” of amyloid is removed. There is ongoing interest in whether removing these fibrils allows for the activation of cardiac stem cells to repair damaged heart muscle, moving the field of amyloidosis from palliative care to true organ restoration.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed:

• Cardiac Biomarkers: NT-proBNP and Troponin T/I to determine Mayo Stage.
• Echocardiogram/Cardiac MRI: To visualize the extent of amyloid thickening.
• Renal Function (eGFR): To monitor kidney involvement.

Precautions During Treatment:

• Monitoring Period: Stay at the clinic for at least 1 hour after the first few infusions to watch for late reactions.
• Weight Tracking: Patients should monitor daily weights, as sudden increases can signal fluid overload or heart stress.

“Do’s and Don’ts” List:

• DO keep track of your “Organ Response” markers (NT-proBNP); these are the best signs that the drug is working.
• DO take all prescribed “pre-meds” exactly as directed before your IV appointment.
• DON’T ignore sudden shortness of breath; in cardiac amyloidosis, this must be evaluated immediately.
• DON’T expect an “instant cure”; removing years of amyloid buildup is a gradual process that takes several months.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Anselamimab is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA). It is available only through participation in approved clinical trials or specialized access programs. Always consult with a qualified hematologist or cardiologist regarding your diagnosis, treatment options, and eligibility for clinical research.